Home > Product Portfolio > Development > Ortataxel
Ortataxel
A third generation taxane classified as a New Chemical Entity (NCE)
Target Indications
- Solid tumors
- Has potential to be active in tumors resistant to paclitaxel and docetaxel
Route of Administration
- Intravenous
- Orally bioavailable
Mode of Action
- Microtubule stabilization leading to mitotic arrest
- Overcomes taxane resistence based on PgP-170 overexpression
Properties
- Safety data from Phase 1 and Phase 2 studies show a similar toxicity/tolerance profile to paclitaxel
Status
|  | Market Opportunities
Status
Phase 2 studies in taxane-refractory solid tumors have indicated a substantial level of antitumor activity
Market
The top (4) taxanes sold over $3 Billion worldwide in 2006.
|